Clinical trials: Prostate Cancer With Intermediate Risk
Prostate Cancer
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00667069
- Testing
- triptorelin, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- 17 sites in France
- Volunteers
- 424 people
- Sponsor
- UNICANCER
Prostate Cancer
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer.
- Trial name
- NCT00045123
- Testing
- tarenflurbil, adjuvant therapy
- Where
- 58 sites in United States
- Sponsor
- Myrexis Inc.
Prostate Cancer
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate.
- Trial name
- NCT05169970
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 7 sites in United States
- Volunteers
- 222 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Hypofractionated Whole Pelvic Radiotherapy of the Prostate
This is a phase I feasibility study to evaluate the feasibility of hypofractionated whole pelvis radiotherapy in 35 patients with biopsy-proven intermediate- to high-risk prostate cancer as defined by NCCN risk criteria.
- Trial name
- NCT02546427
- Testing
- Helical TomoTherapy (HT), CyberKnife SBRT, Permanent Prostate Implant (PPI)
- Sponsor
- Albert J. Chang
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.
The general aim of the study is to describe the use of elective pelvic node irradiation (ENI) in Italy, in patients with intermediate/high/very high-risk prostate cancer patients submitted to adjuvant or radical Radiation Therapy…
- Trial name
- PRO-EPI (NCT03340272)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Prostate Cancer
Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer
The purpose of this study is to observe PSA response and incidence of side effects in patients diagnosed with intermediate to high risk prostate cancer and treated with Cesium-131 in combination of external beam therapy.
- Trial name
- NCT00621413
- Where
- 9 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- IsoRay Medical, Inc.
Prostate Adenocarcinoma
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy)…
- Trial name
- AADLPC (NCT02175212)
- Testing
- Short term androgen deprivation, Long term androgen deprivation
- Where
- Spain
- Volunteers
- 362 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Prostate Cancer
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
The purpose of this research study is to see if patients' tumor can be identified by 18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the…
- Trial name
- NCT04809584
- Testing
- F18-DCFPyL, Gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
- Where
- United States
- Sponsor
- Stanford University
PROSTATE CANCER
Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer
The present study evaluates clinical outcomes and treatment-related toxicity following definitive ultra-high dose external beam radiotherapy delivered with two different regimens in patients with intermediate-risk adenocarcinoma…
- Trial name
- PROSINT (NCT02570919)
- Testing
- IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Fundacao Champalimaud
Prostate Cancer
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA after radiation therapy and identify biomarkers related to…
- Trial name
- NCT00899912
- Testing
- microarray analysis, diagnostic laboratory biomarker analysis
- Where
- 10 sites in United States
- Volunteers
- 13 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer
The purpose of this study is to compare the outcomes of conventionally fractionated conformal radiotherapy with CF-CRT combined with either high-dose-rate brachytherapy or stereotactic body radiotherapy for intermediate or…
- Trial name
- NCT01839994
- Testing
- CF-CRT combined with BT or SBRT boost., CF-CRT alone, Hormonal treatment (neoadjuvant androgen deprivation)
- Where
- Poland
- Volunteers
- 350 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Prostate Cancer
Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial
This project aims to compare the changes in the urinary quality of life (QoL) following focal high dose-rate brachytherapy (HDR-BT) boost to stereotactic ablative radiotherapy (SABR), compared to standard whole gland HDR-BT…
- Trial name
- FORWARD (NCT07300566)
- Testing
- Standard Arm: Whole Gland High Dose Rate Brachytherapy Boost, Experimental Arm: Focal High Dose Rate Brachytherapy Boost
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- Joelle Helou
Prostate Cancer
Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)
This study will enroll prostate cancer patients with an unfavorable intermediate- or high-risk diagnosis. The purpose of this study is to determine whether a regimen of pembrolizumab and low dose prostate radiation or low dose…
- Trial name
- TALON (NCT04569461)
- Testing
- pembrolizumab, Low dose prostate radiation, Radical Prostatectomy
- Where
- United States
- Sponsor
- Duke University
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer
Single Fraction Early Prostate Irradiation (SiFEPI)
Recently, HDR brachytherapy delivering only a 19 Gy fraction was proposed as exclusive treatment for low and intermediate risk prostate cancers.
- Trial name
- SiFEPI (NCT02104362)
- Testing
- exclusive single-fraction irradiation
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
Localized Prostate Carcinoma, Castration-Naive Prostate Cancer
Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer
Clinical studies have shown that magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) of the prostate is safe and effective. In the TULSA procedure, prostate tissue is killed by heating with ultrasound.
- Conditions
- Localized Prostate Carcinoma, Castration-Naive Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate Cancer
- Trial name
- NeoADT-TULSA (NCT05917860)
- Testing
- Degarelix, MRI-guided transurethral ultrasound ablation (TULSA)
- Where
- Finland
- Volunteers
- 15 people
- Sponsor
- Turku University Hospital
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7
Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer
This randomized phase III trial studies a diet and exercise program based on the Diabetes Prevention Program to promote weight loss and improve health in men with low-risk or low-intermediate-risk prostate cancer on active…
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7, Stage IIA Prostate Cancer AJCC v7
- Trial name
- PALS (NCT02454517)
- Testing
- Behavioral Dietary Intervention, Exercise Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Studying samples of blood and tissue from patients with prostate cancer after receiving implant radiation therapy and luteinizing hormone-releasing hormone agonist may help doctors identify biomarkers related to cancer…
- Trial name
- SHIP36B (NCT00898326)
- Testing
- biopsy
- Where
- Japan
- Volunteers
- 198 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Localized Prostate Cancer
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Multi-center, prospective, randomized controlled clinical trial that will compare two treatment methods (PGA with TOOKAD® VTP and Active Surveillance) for treating localized prostate cancer.
- Trial name
- NCT04225299
- Testing
- TOOKAD®
- Where
- United States
- Sponsor
- Steba Biotech S.A.
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene